HEALTHQUIET
9 days ago
Stanford’s 20-year blood-cancer therapy treats first commercial patient; trial found 78% free of GVHD
What's happening
SignalsMonitor is following this as a health story. Times of India World is the outlet attached so far. The first report grouped here was at 8 Oct 2026, 11:30 UTC. The headline in use is “Stanford’s 20-year blood-cancer therapy treats first commercial patient; trial found 78% free of GVHD”. This note is SignalsMonitor's own briefing, not the publisher's article.
What we know
In a remarkable advancement, Stanford researchers have unveiled Orca-T therapy, which has recently received FDA approval. After two decades of rigorous development, this innovative treatment was administered to its inaugural commercial patient, a high-risk leukemia sufferer.
Times of India WorldRead at Times of India World
Story timeline
Reports grouped into this story, earliest first. Exact repeats from the same outlet are collapsed.
- First reported by Times of India World
Reported by 1 outlet
- Times of India